Amneal Pharmaceuticals, Inc. (AMRX) stock
Close on Nov 11, 2026Market cap $6.93BP/E 51.7Yield –
Amneal Pharmaceuticals, Inc. grew revenue 8.9% to $3.20B over the twelve months to Sep 30, 2026. Operating income rose 33.8% to $478.99M, moving the operating margin from 12.2% to 15.0%. Free cash flow was $88.20M, down 66.6% from a year earlier. At the latest close the market valued the company at $6.93B, 51.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $6.93B
- P/E ratio
- 51.7
- Price to sales
- 2.17
- Price to book
- 13.05
- Dividend yield
- –
- Free cash flow yield
- 1.27%
Fundamentals
- Revenue
- $3.20B
- Net income
- $133.30M
- EPS, diluted
- $0.42
- Free cash flow
- $88.20M
- Book value per share
- $1.58
- Diluted shares
- 336M
Trading
- Next earnings
- Feb 26, 2027 (estimated, before the open)
- Previous close
- $21.38
- Open
- $21.47
- Day's range
- $21.44 – $22.00
- Volume
- 2,470,526
- Average volume (20 days)
- 4,277,927
- Index membership
- S&P SmallCap 600 (since Feb 2026), Russell 2000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $11.39 – $22.00
- RSI (14 days)
- 62.9
- Volatility (1 year)
- 35.4%
- Relative volume
- 0.89×
- WACC
- 9.1%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AMRX | S&P 500 | Difference | AMRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.0% | -2.4% | +11.5 pts | ||
| 3 months | +27.0% | -1.2% | +28.1 pts | ||
| Year to date | +72.3% | +12.3% | +60.0 pts | ||
| 1 year | +81.7% | +12.4% | +69.2 pts | ||
| 3 years | +414.5% | +78.8% | +335.6 pts | +72.6% | +21.4% |
| 5 years | +312.7% | +75.2% | +237.6 pts | +32.8% | +11.9% |
| 10 years | +44.7% | +311.1% | −266.4 pts | +3.8% | +15.2% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Amneal Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Amneal Pharmaceuticals
Pharmaceutical Preparations
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes generic, biosimilar, and proprietary branded pharmaceutical products. Its operations are organized into three principal segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment supplies retail generics, sterile injectables, and biosimilars covering a wide range of dosage formulations. The Specialty segment focuses on proprietary branded therapeutics addressing central nervous system conditions, such as Parkinson's disease, and endocrine disorders. Through AvKARE, the company repackages and distributes pharmaceuticals, over-the-counter medications, and medical supplies. Customers include drug wholesalers, retail and mail-order pharmacies, healthcare institutions, and United States governmental bodies.
Company profile, executives and historyAmneal Pharmaceuticals stock: common questions
What is Amneal Pharmaceuticals's stock price?
AMRX closed at $21.71 on Nov 11, 2026, up 1.54% on the day. Over the past 52 weeks it traded between $11.39 and $22.00.
What is Amneal Pharmaceuticals's market cap?
Amneal Pharmaceuticals was worth $6.93B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AMRX's P/E ratio?
AMRX trades at 51.7 times earnings, based on diluted earnings per share of $0.42 over the twelve months to Sep 30, 2026.
How much revenue does Amneal Pharmaceuticals make?
Amneal Pharmaceuticals reported revenue of $3.20B for the twelve months to Sep 30, 2026, up 8.9% from a year earlier.
Does Amneal Pharmaceuticals pay a dividend?
No. Amneal Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Amneal Pharmaceuticals report earnings next?
Amneal Pharmaceuticals is expected to report Q4 FY2026 results on Feb 26, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AMRX stock performed over the past year?
Including dividends, AMRX returned +81.7% over the past year, against +12.4% for the S&P 500.
How many AMRX shares are sold short?
11M shares were sold short at the latest FINRA report, 9.07% of the float, or 2.8 days of average trading volume.
Who are Amneal Pharmaceuticals's competitors?
Companies most similar to Amneal Pharmaceuticals by business, industry and size include ANIP, PRGO, TEVA, ALKS, PBH.
See a number that looks wrong?